# EDGAR Filing Document

**Accession Number:** 0001833141
**File Stem:** 0001833141-26-000016
**Filing Date:** 2026-2
**Character Count:** 5828
**Document Hash:** ee2095d624c686e85f7271335907f250
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001833141-26-000016.hdr.sgml**: 20260218

**ACCESSION NUMBER**: 0001833141-26-000016

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260218

**FILED AS OF DATE**: 20260218

**DATE AS OF CHANGE**: 20260218

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CYBIN INC.
- **CENTRAL INDEX KEY:** 0001833141
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40673
- **FILM NUMBER:** 26647110

**BUSINESS ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9
- **BUSINESS PHONE:** (908) 764-8385

**MAIL ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**<br>**Form 6-K**<br>**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**<br>

For the month of February, 2026.

Commission File Number: **001-40673**

****<br>**<u>Cybin Inc.</u>**<br>(Exact Name of Registrant as Specified in Charter)<br>**100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9** 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠

**INCORPORATION BY REFERENCE**

Exhibit 99.1 of this Form 6-K of Cybin Inc. (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (<u>[File No. 333-292294](https://www.sec.gov/Archives/edgar/data/1833141/000106299325017416/formf10.htm)</u>) of the Company, as amended or supplemented.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br>

---

| | | | |
|:---|:---|:---|:---|
| | | **CYBIN INC.** | **CYBIN INC.** |
| | | (Registrant) | (Registrant) |
| Date: | February 18, 2026 | By: | */s/ Greg Cavers&nbsp;&nbsp;&nbsp;&nbsp;*  |
|  |  | Name: | Greg Cavers |
|  |  | Title: | Chief Financial Officer |

---

------

**<u>EXHIBIT INDEX</u>**

99.1 <u>[Material Change Report dated February 18, 2026](materialchangereporthelus-.htm)</u>

## Exhibit 99.1

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

Cybin Inc., dba Helus Pharma (the "**Company**" or "**Helus**")

100 King Street West, Suite 5600

Toronto, Ontario

M5X 1C9

**Item 2. Date of Material Change**

February 10, 2026

**Item 3. News Release**

A news release disclosing the material change was disseminated by the Company on February 10, 2026, through BusinessWire.

**Item 4. Summary of Material Change**

On February 10, 2026, the Company announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.

**Item 5. Full Description of Material Change**

On February 10, 2026, the Company announced the appointment of Michael Cola as Chief Executive Officer, effective immediately. Mr. Cola's appointment comes at a pivotal moment as Helus advances its pipeline of next-generation mental health therapies toward key clinical and corporate value-inflection milestones.

As President of Shire's Specialty Pharmaceutical business, Mr. Cola helped transform the company into a global central nervous system ("**CNS**") leader, launching and scaling breakthrough therapies. With more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, Mr. Cola brings deep expertise in guiding innovative CNS assets through development and into global markets, building high-performance organizations, and creating long-term shareholder value. His career spans senior leadership roles across R&D, commercialization, corporate strategy, and capital formation, positioning him to lead Helus through its next phase of growth. Earlier in his career, Mr. Cola was one of the founding hires at Merck selected to help create Astra-Merck, one of the most successful pharmaceutical spinouts, formed to commercialize Prilosec. He later held senior leadership roles at AstraZeneca PLC supporting the lifecycle expansion of Prilosec and the transition to Nexium.

More recently, Mr. Cola served as President and CEO of Avalo Therapeutics, Inc., where he led the transition to a rare disease and genomic medicine focus, licensed first-in-class clinical-stage assets, and raised significant funding. He has also served in senior board leadership roles, including as Chairman of Phathom Pharmaceuticals, Inc. and as a former board member of Sage Therapeutics, Inc., supporting organizations through clinical inflection points and commercial launches.

------

Mr. Cola holds a B.A. in Biology from Ursinus College, an M.S. in Biomedical Science and Engineering from Drexel University and studied Bioengineering at the University of Pennsylvania, where he also worked as a biomedical engineer at its affiliated hospital.

**Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

Not applicable.

**Item 8. Executive Officer**

Further information regarding the matters described in this report may be obtained from Gabriel Fahel, Chief Legal Officer of the Company, who is knowledgeable about the details of the material change and may be contacted at 1-866-292-4601.

**Item 9. Date of Report**

February 18, 2026

<br>